First-pass phenomena: Sources of stereoselectivities and variabilities of concentration-time profiles after oral dosage

Chemical Analysis

Volumn 142, Issue , 1997, Pages 573-610

  Spahn Langguth, Hildegard ^a   Benet, Leslie Z ^b   Möhrke, Werner ^c   Langguth, Peter ^d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Procter/Gamble Pharmaceut Germany   (Germany)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347171855     PISSN: 00692883     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (124)

1. Abernethy, D. R., Schwartz, J. B., and Todd, E. L. (1985). Lack of interaction between verapamil and cimetidine. Clin. Pharmacol. Ther., 38, 342-349.
2. Ariens, E. J. (1984). Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin . Pharmacol., 26, 663-668.
3. Benet, L. Z. (1989). Pharmacokinetics: Absorption, distribution and elimination. In B.G. Katzung (ed.), Basic and Clinical Pharmacology. East Norwalk, Appleton & Lange.
4. Berry, B. W. and Jamali, F. (1991). Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat. J. Pharmacol. Exp. Ther., 258, 695-701.
5. Bertilsson, L. (1995). Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet., 29, 192-209.
6. Brockmeier, D., Hajdu, P., Henke, W., Mutschler, E., and Palm, D. (1988). Pharmacokinetics of penbutolol, its effect on exercise heart rate, and in vitro inhibition of radioligand binding using plasma samples. Eur. J. Clin. Pharmacol., 35, 613-623.
7. Buening, M. K., Chang, R. L, Huang, M. T., Fortner, J. G., Wood, A. W., and Conney, A. H. (1981). Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res., 41, 67-72.
8. Caldwell, J. C., Hutt, A. J., and Fournel-Gigleux, S. (1988). The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmacol., 37, 105-114.
9. Chandler, M. H. H., Scott, S. R., and Blouin, R. A. (1988). Age-associated stereoselective alterations in hexobarbital metabolism. Clin. Pharmacol. Ther., 43, 436-441.
10. Dahl, M. L., Johansson, I., Bertilsson, L., et al. (1995). Ultrarapid hydroxylation of debrisoquine in a Swedish population: Analysis of molecular genetic basis. J. Pharmacol. Exp. Ther., 274, 516-520.
11. Dayer, P., Balant, L., Courvoisier, F. et al. (1982). The genetic control of bufuralol metabolism in man. Eur. J. Drug Metab. Pharmacokin., 7, 73-77.
12. de Lannoy, I.A. and Silverman, M. (1992). The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun., 189, 551-557.
13. Ducharme, M. P., Provenzano, R., Dehoorne-Smith, M., and Edwards, D. J., (1993). Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol., 36, 457-459.
14. Eberhart, D. C., Gerrzik, B., Halvorson, M. R., and Parkinson, A. (1991). Species differences in the toxicity and cytochrome P450 III A-dependent metabolism of digitoxin. Mol. Pharmacol., 40, 859-867.
15. Eichelbaum, M., Gross, A. S., and Kroemer, H. K. (1992). Genetic polymorphism in drug metabolism and its role in patient medication. In D. A. Crommelin, and K. K. Midha, eds. 'Topics in Pharmaceutical Sciences 1991.' Stuttgart: Medpharm Scientific Publishers.
16. Endicott, J. A. and Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev., Biochem., 58, 137-171.
17. Fassihi, A.R. (1993). Racemates and enantiomers in drug development. Int. J. Pharm., 92, 1-14.
18. Fritz, P., Behrle, E., Eichelbaum, M., Kroemer, H. K., and Beaune, P. (1993). Expression of cytochrome P4503A in various human tissues. Nanunyn Schmiedeberg's Arch. Pharmacol., 347 (Suppl.), 121.
19. Fuhr, U. and Kummert, A. L. (1995). The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin. Pharmacol. Ther., 58, 365-373.
20. Fuhr, U., Kroemer, H. K., and Schymanski. P. (1993). Effects of naringenin and naringin on verapamil metabolism in human liver microsomes. Naunyn Schmiedeberg's Arch. Pharmacol., 347 (Suppl.), R31.
21. Fuhr, U., Harder, S., Lopez-Rojas, P., Müller-Peltzer, H., Kern, P., and Staib, A. H. (1994). Increase verapamil concentrations in steady state by coadministration of grapefruit juice. Naunyn Schmiedeberg's Arch. Pharmacol., 349 (Suppl.), R134.
22. Gietl, Y., Spann, H., and Mutschler, E. (1988). Simultaneous determination of R- and S-prenylamine in plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. Biomed. Appl., 426, 305-314.
23. Gietl, Y., Spahn, H., and Mutschler, E. (1989). Enantioselective disposition of R-(-)-and S-(+)-prenylamine in the rat. Arzneim.-Forsch./Drug Res., 39, 853-856.
24. Gietl, Y., Spahn, H., Knauf, H., and Mutschler, E. (1990). Single- and multiple-dose pharmacokinetics of R-(-)- and S-(+)-prenylamine in man. Eur. J. Clin. Pharmacol., 38, 587-593.
25. Gilmore, D. A., Gal, J., Gerber, J. G., and Nies, A. S. (1992). Age and gender influence the stereoselective pharmacokinetics of propranolol. J. Pharmacol. Exp. Ther., 261, 1181-1186.
26. Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., and Benet, E. Z. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther., 58, 15-19.
27. Gonzalez, F. J. (1992). Human cytochrome P450: Problems and prospects. Trends Pharmacol. Sci., 13, 346-352.
28. Gosland, M., Tsuboi, C., Hoffman, T., Goodin, S. and Vore, M. (1992). 17-β-Estradiol glucuronide: An inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Res., 53, 5382-5385.
29. Gottesman, M. M. (1993). How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53, 747-754.
30. Gottesman, M. M. and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem., 62, 385-427.
31. Gross, A. S., Mikus, G., Fischer, C., Hertrampf, R., Gundert-Remy, U., and Eichelbaum, M. (1989). Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metabolizer phenotype. Br. J. Clin. Pharmol., 28, 555-566.
32. Gupta, S. K., Bakran, A., Johnson, R. W. G., Hebert, M. F., and Benet, L. Z. (1989). Cyclosporine-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol., 27, 475-481.
33. Gustavson, L. E. and Benet, L. Z. (1994). Menopause: Pharmacodynamics and pharmacokinetics. Exp. Gerontol., 29, 437-444.
34. Gustavson, L. E., Legier, U. F., and Benet, L. Z. (1986). Impairment of prednisolone disposition im women taking oral contraceptives or conjugated estrogens. J. Clin. Endocrinol. Metab., 62, 234-237.
35. Gut, J., Gasser, R., Dayer, P., Kronbach, T., Catin, T., and Meyer, U.A. (1984). Debrisoquine-type polymorphism in drug oxidation: Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett., 173, 287-290.
36. Harder, S., Thürmann, P., Siewert, M., Blume, H., Rietbrock, N., van der Kleijn, J., and Gierend, M. (1992). Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients. J. Cardiovasc. Pharmacol., 19, 665-669.
37. Harris, R. Z., Benet, L. Z., and Schwartz, J. B. (1995). Gender effects in pharmacokinetics and phrmacodynamics. Drugs, 50, 222-239.
38. Hebert, M. F., Roberts, J. P., Prueksaritanont, T., and Benet, L. Z. (1992). Bioavailability of cyclosporine with concomitant rifampicin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther., 52, 453-155.
39. Henke, W., Spahn, H., von Möllendorf, E., and Mutschler, E. (1985). Pharmacokinetics of the enantiomers of the β-adrenoceptor blocking carvedilol. Paper presented at the annual meeting of the German Pharmaceutical Society, Braunschweig.
40. Henke, W., Henke, D., and Spahn-Langguth, H. (1992). The influence of cimetidine on the stereopharmacokinetics of carvedilol. Naunyn Schmiedeberg's Arch. Pharmacol., 345 (Suppl.), R9.
41. Hooper, W. D. and Qing, M. S. (1990). The influence of age and gender on the stereo-selective metabolism and pharmacokinetics of mephobarbital in humans. Clin. Pharmacol. Ther., 48, 633-640.
42. Hunt, C. M., Westerkam, W. R., and Stave, G. M. (1992). Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol., 44, 275-283.
43. Jamali, F., Mehvar, R., and Pasutto, F.M., (1989). Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J. Pharm. Sci., 78, 695-715.
44. Jamali, F., Mehvar, R., Russell, A. S., Sattari, S., Yakimets, W. W., and Koo, J. (1992). Human pharmacokinetics of ibuprofen following different doses and formulations: Intestinal chiral inversion. J. Pharm. Sci., 81, 221-225.
45. Jonkers, R. E., Koopmans, R. P., Portier, E. J. G., and van Boxtel, C. J. (1991). Debrisoquine phenotype and the pharmacokinetics and beta-2-receptor pharmacodynamics of metoprolol and its enantiomers. J. Pharmacol. Exp. Ther., 256, 959-966.
46. Karim, A. and Piergies, A. (1995). Verapamil steroisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin. Pharmacol. Ther., 58, 174-184.
47. Kato, R. and Yamazone, Y. (1992). Sex-specific cytochrome P450 as a cause of sex-and species-related differences in drug toxicity. Toxicol Lett., 64, 661-667.
48. Kirch, W., Ohnhaus, E. E., Zekorn, C., Eichelbaum, M., Spahn, H., and Mutschler, E. (1985). Pharmacokinetics of metoprolol in relation to polymorphic sparteine oxidation. Arch. Toxicol., 8 (Suppl.), 401-402.
49. Klaassen, C. D. (1988). Intestinal and hepatobiliary disposition of drugs. Toxicol Pathol., 16, 130-137.
50. Kober, S., Spahn-Langguth, H., Kurz, A., Zaigler, M., Fuhr, U., and Mutschler, E. (1996). Triamterene hydroxylation in human liver microsomes is mediated by the cytochrome P450 isoform CYP1A2. Arch Pharmacol., 353 (Suppl.), R157.
51. Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W.O., Schuetz, J., Wrighton, S. A., and Watkins, P. B. (1992). Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology, 102, 1186-1198.
52. Krähenbühl, S. and Reichen, J. (1988). Canalicular bile flow and bile salt secretion are maintained in rats with liver cirrhosis. Further evidence for the intact hepatocyte hypothesis. J. Hepatol., 7, 63-71.
53. Kroemer, H. K., Echizen, H., Heidemann, H., and Eichelbaum, M. (1992). Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of the individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther., 260, 1052-1057.
54. Kuhlmann, J. and Weihrauch, T. R. (1995). Food-drug interactions. Clinical Pharmacology, Vol. 12. W. Zuckschwedt Verlag, München., pp. 34-56.
55. Kurz, A., Jensen, C., Mutschler, E., Schloos, J., and Spahn-Langguth, H. (1994a). Stereoselectivities in carvedilol phase-I metabolism: Studies with human liver microsomes. Naunyn Schmiedeberg's Arch. Pharmacol., 349 (Suppl.).
56. Kurz, A., Fuhr, U., Mutschler, E., Staib, A. H., and Spahn-Langguth, H. (1994b). Characterization of phase-I metabolism of carvedilol in human liver microsomes. Eur. J. Pharm. Sci., 2, 171.
57. Langguth, P., Möhrke, W., Möhler, H., and Spahn-Langguth, H. (1997). Drug absorption via intestinal vs. nasal mucosae: Dependence of rate and extent of systemic availability of tranylcypromine enantiomers upon the application site. Biopharm. Drug Dispos., (submitted for publication).
58. Lennard, M. S., Tucker, G. T., Silas, J. H., Freestone, S., Ramsey, L. E., and Woods, H. F. (1983). Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin. Pharmacol. Ther., 34, 732-737.
59. Lennard, M. S., Tucker, G. T., and Woods, H. F. (1986). The polymorphic oxidation of β-adrenoceptor antagonists. Clin. Pharmackinet., 11, 1-17.
60. Lennard, M. S., Lewis, R. V., Brawn, L. A., Tucker, G. T., Ramsey, L. E., Jackson, P. R., and Woods, H. F. (1989). Timolol metabolism and debrisoquine oxidation polymorphism: A population study. Br. J. Clin. Pharmacol., 27, 429-434.
61. Levy, R. H. and Boddy, A. V. (1991). Stereoselectivity in pharmacokinetics: A general theory. Pharm. Res., 8, 551-556.
62. Lim, W. H., and Hooper, W. D. (1989). Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans. Drug Metab. Dispos., 17, 212-217.
63. Lindner, M., Rath, M., Stoschitzky, and Semmelrock, H. J. (1989). Pharmacokinetic data of propranolol enantiomers in a comparative human study with (S)- and (R,S)-propranolol. Chirality, 1, 10-13.
64. Longstreth, J. A. (1993). Verapamil. A chiral challenge to the pharmacokinetic and pharmacodynamic assessment of bioavailability and bioequivalence. In I.W. Wainer (ed.) Drug Stereochemistry: Analytical Methods and Pharmacology, 2nd ed. New York: Marcel Dekker.
65. Marzo, A., Cardace, G., and Arrigoni Martinelli, E. (1992). Enzymes in stereoselective pharmacokinetics of endogenous substances. Chirality, 4, 247-251.
66. Mayer, S., Spahn-Langguth, H., Gikalov, I., and Mutschler, E. (1993). Pharmacokinetics of beclobric acid enantiomers and their glucuronides after single and multiple p.o. dosage of rac-beclobrate. Arzneim-Forsch/Drug Res., 42:2, 40-43.
67. McGourty, J. C., Silas, J. H., Lennard, M. S., Tucker, G. T., and Woods, J. W. (1985a). Metoprolol metabolism and debrisoquine oxidation polymorphism - population and family studies. Br. J. Clin. Pharmacol., 20, 555-566.
68. McGourty, J. C., Silas, J. H., Fleming, J. J., McBurney, A., and Ward, J. W. (1985). Pharmacokinetics and β-blocking effects of timolol in poor and extensive metabolizers of debrisoquine. Clin. Pharmacol. Ther., 38, 409-413.
69. Mehvar, R. (1992). Input rate-dependent stereoselective pharmacokinetics: enantiomeric oral availability and blood concentration ratios after constant oral input. Biopharm. Drug. Dispos., 13, 597-615.
70. Mehvar, R. (1994). Input rate-dependent stereoselective pharmacokinetics: Effect of pulsatile oral input. Chirality, 6, 185-195.
71. Meijer, D. K. F. (1987). Current concepts on hepatic transport of drugs. J. Hepatol., 4, 259-268.
72. Meijer, D. K. F. and Groothuis, G. M. M. (1991). Hepatic transport of drugs and proteins. In Oxford Textbook of Clinical Hepatology, Vol. 1. N. McIntyre, J. P. Benhamour, J. Bircher, M. Rizzetto, J. Rodes (eds.), Oxford: Oxford University Press, pp. 40-78.
73. Meijer, D. K. F., van der Sluijs, P. (1989). Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery. Pharm. Res., 6, 105-118.
74. Mikus, G., Eichelbaum, M., Fischer, C., Gumulka, S., Klotz, U., and Kroemer, H. K. (1990). Interaction of verapamil and cimetidine: Stereochemical aspects of drug metabolism, drug disposition and drug action. J. Pharmacol. Exp. Ther., 253, 1042-1048.
75. Minchin, R. F. and Ilett, K. F. (1982). Presystemic elimination of drugs: Theoretical considerations for quantifying the relative contribution of gut and liver. J. Pharm. Sci., 71, 458-460.
76. Murray, M. and Reidy, G. F. (1990). Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharm. Res., 42, 85-101.
77. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. W, Gotoh, O., Okuda, K., and Nebert, D. W. (1993). The P450 Superfamily: Update of new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol., 12, 1-51.
78. Neugebauer, G. and Neubert, P. (1991). Metabolism of carvedilol in man. Eur. J. Drug. Metab. Dispos., 16, 257-260.
79. Neugebauer, G., Akpan, W., Kaufmann, B., and Reiff, K. (1990). Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol., 38, S108-S111.
80. Neugebauer, G., Gabor, M., and Reiff, K. (1992). Disposition of carvedilol enantiomers in patients with liver cirrhosis: Evidence for disappearance of stereoselective first-pass extraction. J. Cardiovasc. Pharmacol., 19 (Suppl. 1), S142-S146.
81. Nuggehally, R. S., Hubbard, J. W., Quinn, D., Korchinski, E. D., and Midha, K. K. (1991). Extensive and enantioselective presystemic metabolism of DL-threomethylphenidate in humans. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 15, 213-220.
82. Nuggehally, R. S., Hubbard, J. W., Korchinsky, E. D., and Midha, K. K. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm., Res., 10, 14-21.
83. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., and Woods, H. F. (1988). Use of quinidine inhibition to define the role of sparteine/debrisoquine cytochrome P-450 in metoprolol oxidation by human liver mnicrosomes. J. Pharmacol. Exp. Ther., 247, 242-247.
84. Otton, S. V., Lennard, M. S., Tucker, G. T., and Woods, H. F. (1989). Cumene hydroperoxide-supported oxidation of propranolol enantiomers by human liver microsomes. Eur. J. Clin. Pharmacol., 36 (Suppl.), 66.
85. Oude Elferink, R. P., Meijer, D. K., Kuipers, F., Jansen, P. L., Groen, A. K., and Groothuis, G. M. (1995). Hepatobiliary secretion of organic compounds: Molecular mechanisms of membrane transport. Biophys. Acta, 1241, 215-268.
86. Paar, W. D., Brockmeier, D., Hirzebruch, M., Schmidt, E. K., von Unruh, G. E., and Dengler, H. J. (1990). Pharmacokinetics of prenylamine racemate and enantiomers in man. Arzneim-Forsch/Drug Res., 40 :1, 657-661.
87. Parke, P. V., loannides, C, and Lewis, D. F. V. (1990). The 1990 pharmaceutical manufacturers association of Canada keynote lecture. The role of the cytochrome P450 in the detoxication and activation of drugs and other chemicals. J. Physiol. Pharmacol., 69, 537-549.
88. Perotti, B. Y. T., Okudaira, N., Prueksaritanont, T., and Benet, L. Z. (1994). FK 506 metabolism in male and female rat liver microsomes. Drug Metab. Dispos., 22, 85-89.
89. Raghuram, R. C., Koshakji, R. P., Wilkinson, G. R., and Wood, A. J. J. (1984). Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol. Ther., 36, 51-56.
90. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Trager, W. F. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P-4502C9 in the ethiology of the (S)-warfarin drug interaction. Chem. Res. Toxicol., 5, 54-59.
91. Roepe, P. D. (1995). The role of the MDR protein in altered translocation across tumor cell membranes. Biochim. Biophys. Acta, 1241, 385-406.
92. Rosenthal, J., Aschoff, A., Bühler, G., Hahn, G., Mutschler, E., Spahn-Langguth, H., Möhrke, W., and Völger, K. D. (1992): Pharmacokinetics and pharmacodynamics of verapamil isomers after administration of immediate- and sustained-release racemic verapamil dosage forms. Clin. Pharmacol. Ther., 51, 153.
93. Rowland, M. and Tozer, T. N. (1989). Clinical Pharmacokinetics. Lea & Febiger, Philadelphia, pp. 148-176.
94. Schwartz, J. B., Troconiz, I. F., Verotta, D., Liu, S., and Capili, H. (1993). Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J. Pharmacol. Exp. Ther., 265, 690-698.
95. Schwartz, J. B., Capili, H., and Wainer, I. W. (1994). Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers. Clin. Pharmacol. Ther., 56, 368-376.
96. Silber, B., Holford, N. H. G., and Riegelman, S. (1971). Stereoselective disposition and glucuronidation of propranolol in humans. J. Pharm. Sci., 71, 1043-1044.
97. Soldner, A., Spahn-Langguth, H., Voith, B., Stapff, M., and Mutschler, E. (1996). Losartan and EXP 3174 in rats: Concentrations in central and peripheral compartments as basis for PK/PD correlations. (Submitted for publication).
98. Spahn, H. (1989). Characterization of stereochemical processes in drug metabolism and pharmacokinetics. Habilitation thesis. Johann Wolfgang Goethe-University Frankfurt/Main.
99. Spahn, H., Henke, W., Langguth, P., Schloos, J., and Mutschler, E. (1990). Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen for chiral derivatization. Arch. Pharm. (Weinheim, Ger.), 323, 465-469.
100. Spahn-Langguth, H., Hahn, G., Mutschler, E., Möhrke, W., and Langguth, P. (1992). Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. J. Chromatogr., 584, 229-237.
101. Spahn-Langguth, H., Hahn, G., Mutschler, E., Elze, M., Potthast, H., Blume, H., and Möhrke, W. (1994). Determination of the bioavailability of tranylcypromine with a stereospecific assay. Eur. J. Pharm. Sci., 2, 160.
102. Spahn-Langguth, H., Möhrke, W., and Langguth, P. (1994b). Variabilities and discontinuities in TCP input profiles following oral administration. Eur. J. Pharm. Sci., 2, 160.
103. Stahl, E., Baumgartner, U., Krauss, D. Spahn-Langguth, H., Mutschler, E., Schölmerich, J. (1990): Pharmacokinetics of carvedilol enantiomers in rats with portacaval shunt after racemate dosing. Naunyn-Schmiedeberg's Arch Pharmacol., 341 (Suppl.), R4.
104. Stahl, E. (1993). Stereochemische Aspekte der Pharmakokinetik der lipophilen β-Adrenozeptor-Antagonisten Carvedilol und Propranolol. Ph.D. thesis, Department of Pharmacy, Johann Wolfgang Goethe-University, Frankfurt/Main.
105. Stahl, E., Henke, D., Mutschler, E., and Spahn-Langguth, H. (1993a). Saturable enantioselective first-pass effect for carvedilol after high racemate doses in rats. Arch. Pharm. (Weinheim, Ger.), 326, 123-125.
106. Stahl, E., Baumgartner, U., Mutschler, E., and Spahn-Langguth, H. (1993b). Carvedilol stereopharmacokinetics in rats: Affinities to blood constituents and tissues. Arch. Pharm. (Weinheim, Ger.), 326, 529-533.
107. Stahl, E., Baumgartner, U., Henker, D., Schölmerich, J., Mutschler, E., and Spahn-Langguth, H. (1993c). Rats with portocaval shunt as a potential pharmacokinetic model for liver cirrhosis. Chirality, 5, 120-125.
108. Steen, H., and Meijer, D. K. F. (1991). Organic cations. Prog. Pharmacol. Clin. Pharmacol., 8(4), pp. 239-272.
109. 2-antagonist interaction. Clin. Pharmacol. Ther., 43, 283-289.
110. Tucker, G. T. and Lennard, M. S. (1990). Enantiomer specific pharmacokinetics. Pharmacol. Ther., 45, 309-329.
111. Vestal, R. E. (1989). Aging and determinants of hepatic drug clearance. Hepatology, 9, 331-333.
112. Vogelgesang, B., Echizen, H., Schmidt, E., and Eichelbaum, M. (1984). Stereoselective first-pass metabolism of highly cleared drugs: Studies of the bioavailability of L-and D-verapamil examined with a stable isotope technique. Br. J. Clin. Pharmacol., 18, 733-740.
113. Wacher, V. J., Wu, C. Y., and Benet, L. Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13, 129-134.
114. Walle, T. and Walle, U. K. (1986). Pharmacokinetic parameters obtained with racemates. Trends Pharmacol. Sci., 7, 155-158.
115. Walle, T., Webb, J. G., Bagwell, E. E., Walle, U. K., Daniell, H. B., and Gaffney, T. E. (1988). Stereoselective delivery and actions of beta-receptor antagonists. Biochem. Pharmacol., 37, 115-124.
116. Ward, S. A., Walle, T., Walle, U. K., Wilkinson, G. R., and Branch, R. A. (1989). Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin. Pharmacol. Ther., 45, 72-79.
117. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Korzekwa, K. (1992). Steroid hormone hydroxylase specificities of eleven cDNA-expressed cytochrome P450s. Arch. Biochem. Biophys., 290, 160-166.
118. Weber-Grandke, H., Hahn, G., Mutschler, E., Möhrke, W., Langguth, P., and Spahn-Langguth, H. (1993). The pharmacokinetics of tranycypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br. J. Clin. Pharmacol., 36, 363-365.
119. Wetterich, U., Spahn-Langguth, H., Mutschler, E., Terhaag, B., Rösch, W., Langguth, P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res., 13, 526-534.
120. Woodruff Modi, M., Hassett J. M., and Lalka, D. (1988). Influence of posture on hepatic perfusion and the presystemic biotransformation of propanolol. Simulation of the food effect. Clin Pharmacol. Ther., 44, 268-274.
121. Wosilait, W. D. and Lueck, R. H. (1988). Multifactorial modeling, drug interactions, liver damage and aging. Gen. Pharmacol., 19, 143-151.
122. Wu, C. Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., and Wacher V. J. (1995). Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol. Ther., 58, 492-497.
123. Wynne, H. A., Cope, L. H., and Mutch, E. (1989). The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 9, 297-301.
124. Zhou, H. H. and Wood, A. J. J. (1995). Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther., 57, 518-520.